An Overview of Pritor^®/Kinzal^®:
the only cardiometabolic ARB

Pritor^®/Kinzalmono^® (telmisartan) is an angiotensin receptor blocker (ARB) indicated for the treatment of essential hypertension, and also for the reduction of cardiovascular morbidity in patients with:¹

1. Manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease)

OR

2. Type 2 diabetes mellitus with documented target organ damage.

PritorPlus^®/Kinzalkomb^® (telmisartan/hydrochlorothiazide) is indicated in hypertensive patients whose blood pressure is not adequately controlled on telmisartan alone.¹

Dual activity

Telmisartan (Pritor^®/Kinzal^®) is an Angiotension Receptor Blocker (ARB) with dual activity, acting through AT1 receptor blockade and selective PPAR-γ (peroxisome proliferator-activated receptor-gamma) modulation to provide strong blood pressure control with potential additional metabolic benefits.²

Strong blood pressure control

Reduction in systolic blood pressure is one of the key factors in minimising cardiovascular risk. Pritor^®/Kinzal^® has demonstrated a stronger reduction in both systolic and diastolic blood pressure compared to other ARBs.³

Efficacy maintained over 24 hours with a single dose

Pritor^®/Kinzal^® provides control of hypertension over a 24-hour period including the critical 6 morning hours during which hypertensive patients are at increased risk of stroke and myocardial infarction.⁴

Cardiovascular and renal protection

The recently published ONTARGET^® and PROTECTION^® study programmes have demonstrated Pritor^®/Kinzal^®'s cardiovascular and renal protection.

The ONTARGET^® trial has shown that Pritor^®/Kinzal^® is as effective as ramipril in reducing the risk of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure (combined endpoint) in high cardiovascular risk patients, but with better tolerability. There were more discontinuations in the ramipril group than in the Pritor^®/Kinzal^® group due to angio-oedema and cough, although more patients in the Pritor^®/Kinzal^® group discontinued because of hypotensive symptoms.⁵

In addition, the PROTECTION^® study programme has demonstrated Pritor^®/Kinzal^®’s renoprotective effect across the renal continuum.⁶

For more information on these trials along with the data and opinions from leading experts on the potential implications for clinical practice, please visit www.ICMAedu.com.

High tolerability, even in ACE Inhibitor tolerant patients

In the ONTARGET^® trial, despite greater discontinuation due to hypotensive symptoms, overall Pritor^®/Kinzal^® was associated with greater tolerability and higher treatment compliance than the comparator ACE inhibitor ramipril, even amongst an entirely ACE inhibitor tolerant population.⁵

Additional metabolic benefits

Through its dual mode of action, Pritor^®/Kinzal^® influences blood pressure and has potential to improve other cardiometabolic risk factors. AT1 receptor inhibition results in significant blood pressure reduction whilst selective PPAR-γ modulation (SPPARM) may improve associated metabolic parameters including lipid and glucose levels.⁷

For more information on the benefits of Pritor^®/Kinzal^® please consult the following detailed pages:

References:

1 Pritor Prescribing Information
2 Benson SC et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004 May; 43(5): 993-1002.
3 Neutal et al. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5; 58-63
4 White et al. Effects of the Angiotensin II Receptor Blockers Telmisartan Versus Valsartan on the Circadian Variation of Blood Pressure. Am J Hypertens 2004;17: 347–353
5 The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008;358:1547-59.
6 PROTECTION programme
7 Kurtz et al. Journal of hypertension 2004; 22: 2253-2261

Patient's Home If you are a patient,
please enter the
patient's website.